Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

NCT02266745 is registered in ClinicalTrials.gov with Promontory Therapeutics Inc. as lead sponsor.

NCT NCT02266745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02266745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Lead sponsor
Promontory Therapeutics Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2014
Completion date
April 1, 2025
Enrollment
109 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, crpc, genital neoplasms, male, mcrpc, metastatic castrate-resistant prostate cancer, neoplasms by site, prostatic neoplasms, pt-112, urogenital neoplasms